Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 2/20 | 0.30 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.30 |
| ▸ | MAP3K11 | Q16584 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9921771 | 0.90 | KDM4E (0.39) | PRKCAPRKCQMAP3K11 | |
| SCHEMBL9918548 | 0.81 | JAK2 (0.36) | PRKCAPRKCQMAP3K11 | |
| SCHEMBL9921780 | 0.79 | ALDH1A1 (0.47) | — | |
| SCHEMBL9918554 | 0.71 | PDE3B (0.40) | PRKCAPRKCQMAP3K11 | |
| SCHEMBL9918552 | 0.71 | HTT (0.39) | — | |
| SCHEMBL9921664 | 0.70 | MAP3K11 (0.41) | MAP3K11 | |
| SCHEMBL9918533 | 0.69 | MAP3K11 (0.41) | MAP3K11 | |
| SCHEMBL9918547 | 0.69 | JAK2 (0.32) | MAP3K11 | |
| SCHEMBL9918551 | 0.68 | MAP3K11 (0.35) | PRKCAPRKCQMAP3K11 | |
| SCHEMBL9918557 | 0.67 | LRRK2 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149662-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149662-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | JAK2, JAK1, JAK3 | PRKCA 112/4885PRKCQ 264/4885MAP3K11 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.